Clicky

Terns Pharmaceuticals, Inc.(TERN)

Description: Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase 2a clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase 1 clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Foster City, California.


Keywords: Biopharmaceutical Organ Systems Hepatitis Peptide Hormones Steatohepatitis Non Alcoholic Fatty Liver Disease Glucagon Liver Anti Diabetic Drugs Bile Acid Chronic Liver Diseases Tropifexor

Home Page: www.ternspharma.com

TERN Technical Analysis

1065 East Hillsdale Boulevard
Foster City, CA 94404
United States
Phone: 650 525 5535


Officers

Name Title
Mr. Senthil Vel Sundaram CEO & Director
Dr. Erin Quirk M.D. Pres & Head of R&D
Mr. Seokho Yoon Esq. COO, Gen. Counsel & Sec.
Dr. Weidong Zhong Ph.D. Co-Founder & Exec. Officer
Dr. Mark Joseph Vignola CFO & Treasurer
Dr. Jeffrey R. Jasper Ph.D. Sr. VP & Head of Research
Ms. Diana Chung Sr. VP & Chief Devel. Officer
Dr. Kerry Russell M.D., Ph.D. Chief Medical Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.3392
Price-to-Sales TTM: 256.5261
IPO Date: 2021-02-05
Fiscal Year End: December
Full Time Employees: 41
Back to stocks